Researchers at the University of California, Irvine have developed a 3D human colon model integrated with bioelectronics to aid in colorectal cancer research and drug discovery. The “3D in vivo mimicking human colon” enables precision, personalized medicine and offers a more ethical, accurate and cost-effective alternative to traditional animal testing.
Stem cells in most organisms typically take cues from adjacent cells. But new research from the Stowers Institute for Medical Research reveals planarian stem cells ignore their nearest neighbors and instead respond to signals farther away in the body. This discovery may help explain the flatworm’s extraordinary ability to regenerate—and could offer clues for developing new ways to replace or repair tissues in humans.
The influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally. In the U.S. alone, it is estimated that despite seasonally updated vaccines, IAV infections still lead to 140,000 to 710,000 hospitalizations and 12,000 to 52,000 deaths annually.
Faulty versions of the LMNA gene can cause a wide range of health problems, including heart muscle disease (dilated cardiomyopathy) and muscle weakness (muscular dystrophies). Many of these diseases are caused by single-point mutations, which are changes to one DNA “letter” (base).
A study by the University of Portsmouth in England has mapped the biological journey of anxiety in the brain when people are faced with a no-win situation.
Researchers at Cincinnati Children’s Hospital Medical Center in collaboration with Roche, have developed a next-generation human liver organoid microarray platform that could help predict which drugs may cause harmful immune reactions in some people.
Researchers at NYU Abu Dhabi (NYUAD) have developed a new type of brain implant that can deliver drugs to multiple regions of the brain with high precision, offering fresh possibilities for the treatment of neurological disorders.
Wearable ultrasound devices are actively used in various medical settings, including hospital diagnostics, rehabilitation monitoring, and telemedicine. However, most commercial devices currently rely on lead (Pb)-based piezoelectric ceramics, which are harmful to the human body and the environment, making it difficult to ensure both performance and safety.
The blood-based biomarker test was developed in partnership with Eli Lilly and Company.
MSU’s Technology Transfer Office is facilitating the commercialisation process of the device.